Asia-Pacific Stroke Management Market Expected to Reach $3.25 Billion by 2035

According to a new report published by Allied Market Research, titled, “Asia-Pacific stroke management market: Opportunity Analysis and Industry Forecast, 2024–2035," The Asia-Pacific stroke management market size was valued at $1.74 billion in 2023 and is projected to reach $3.25 billion by 2035, registering a CAGR of 5.3% from 2024 to 2035. The ischemic stroke segment is expected to register the highest CAGR of 5.4% during the forecast period.

A stroke is a medical emergency where the blood supply to part of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients, leading to brain cell death. Stroke management involves immediate treatment to restore blood flow or control bleeding, followed by rehabilitation to aid recovery and prevent recurrence. This includes administering medications such as thrombolytics for ischemic stroke, blood pressure control, lifestyle changes, and therapy for physical, speech, and occupational recovery. Continuous monitoring and education for patients and caregivers are crucial to manage risk factors and enhance long-term outcomes.

The stroke management market is experiencing significant growth driven by the increasing geriatric population, which is more susceptible to strokes due to age-related risk factors such as hypertension, atrial fibrillation, and diabetes. According to Population Reference Bureau (PRB), 2023, the Asia region has the world’s oldest population and Japan is at the top with 28% of aged individuals. This demographic shift necessitates enhanced stroke management solutions, encompassing prevention, acute treatment, and rehabilitation.

Additionally, various initiatives by key players and organizations are further contributing to market expansion. For instance, in May 2024, Zydus Hospitals, Ahmedabad, and India Medtronic announced a partnership to support stroke patients in Gujarat via a hub and spoke network. This collaboration aims to create an ecosystem that facilitates timely diagnosis and treatment of stroke patients, leveraging indigenous artificial intelligence (AI)-enabled technology. Medtronic is expected to work with Zydus Hospitals to provide tools and technologies, as well as education and training for doctors in selected remote hospitals. Such initiatives enhance the capabilities of healthcare providers to manage strokes more effectively, particularly in underserved areas. 

By improving access to advanced diagnostic and therapeutic tools, and bolstering healthcare infrastructure and professional training, these strategic collaborations play a crucial role in driving the growth of the stroke management market.

The Asia-Pacific stroke management market is segmented on the basis of type, application, end user, and country. Depending on the type, the market is segmented into therapeutics and surgery. The therapeutics segment is further classified into tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive. The surgery segment is further classified on the basis of device including thrombectomy, carotid endarterectomy, craniotomy, and hydrocephalus shunt and by end user including hospitals & clinics, ambulatory surgical centers, and others. The thrombectomy segment is further classified into mechanical thrombectomy, aspiration thrombectomy, and rheolytic thrombectomy. The therapeutics segment dominated the market share in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to advances in drug development and approval of new medications significantly improved treatment outcomes for stroke patients. In addition, increased awareness and early diagnosis driven demand for effective therapeutic interventions, which further contributed to the growth of the therapeutics segment.

Depending on the application, the market is segmented into ischemic stroke, and hemorrhagic stroke. The ischemic stroke segment dominated the market share in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to rise in prevalence of ischemic strokes, advances in diagnostic imaging and thrombolytic therapies and increase in public awareness and early intervention strategies contributed to the dominance of this segment.

Country wise, rest of Asia-Pacific was the largest shareholder in the Asia-Pacific stroke management market in 2023 owing to well-established healthcare infrastructure and robust R&D ecosystem facilitate the adoption of innovative stroke management technologies and therapies. In addition, government initiatives and healthcare policies prioritize stroke prevention, early detection, and comprehensive treatment strategies, further boosting the market growth.

However, China is anticipated to register the highest CAGR during the forecast period owing to rising awareness about stroke prevention, coupled with increasing healthcare expenditure facilitates improved access to diagnosis and treatment options across urban and rural areas. Furthermore, advancements in digital health technologies enable remote monitoring and timely intervention, particularly in underserved regions where traditional healthcare infrastructure is limited or unavailable will potentially drive the market growth.

Key Findings of the Study

• On the basis of type, the therapeutics segment dominated the market in 2023 and is anticipated to grow at the highest CAGR during the forecast period.
• On the basis of application, the ischemic stroke segment dominated the market in 2023 and is anticipated to grow at the highest CAGR during the forecast period.
• Region wise, the rest of Asia-Pacific generated the largest revenue in 2023. However, China is anticipated to grow at the highest CAGR during the forecast period.